Summary
The Revolutionary Proposal Linking Drug Prices to International Standards under the Trump Plan refers to a policy initiative aimed at reducing the high cost of prescription drugs in the United States by benchmarking U.S. drug prices against those paid in comparable high-income countries. Often described as the “most-favored nation” (MFN) pricing model or international reference pricing (IRP), the proposal sought to cap Medicare Part B drug payments at levels no higher than the lowest prices available among a selected group of Organisation for Economic Co-operation and Development (OECD) countries, adjusted for per-capita gross domestic product (GDP). This approach marked a significant departure from traditional U.S. pharmaceutical pricing policies, where prices have historically remained substantially higher than in other developed nations.
Introduced during the Trump administration as part of broader efforts to tackle rising drug costs, the proposal was positioned as a mid-level priority and reflected an innovative yet contentious strategy to address escalating Medicare drug spending, projected to save taxpayers billions over seven years. The plan entailed regulatory changes requiring drugs imported under this model to meet stringent U.S. standards for labeling, authenticity, and safety overseen by the Food and Drug Administration (FDA), highlighting the administration’s attempt to balance cost reduction with public health protections.
The proposal ignited considerable controversy and opposition, particularly from the pharmaceutical industry, which viewed it as a threat to innovation and the existing business model. Industry groups such as PhRMA lobbied aggressively against the policy, warning that tying U.S. prices to international benchmarks could disrupt global pricing dynamics and potentially lead to price increases in foreign markets. Critics also raised concerns that the policy might undermine incentives for research and development, potentially impacting the availability of new therapies and resulting in adverse health outcomes.
Although the MFN rule was introduced as an interim final rule before the end of the Trump administration, it faced legal challenges and had yet to be fully implemented. Its future remains uncertain amid ongoing debate over the balance between lowering drug costs for American patients and preserving pharmaceutical innovation, as well as questions about the practical complexities of comparing drug prices across different national healthcare systems.
Background
International reference pricing (IRP) has emerged as a prominent strategy in efforts to address the high cost of prescription drugs in the United States. The approach involves benchmarking U.S. drug prices against those in a select group of high-income countries, thereby aiming to establish a reference price index and restrict U.S. prices to a narrow range within that index. This concept gained particular attention during the Trump administration, where it was explored as a mid-level priority within broader initiatives to lower drug prices.
In principle, pharmaceutical companies have shown some openness to innovative pricing arrangements, including outcome-based contracts with insurers, though they have expressed concerns about government regulations such as Medicaid’s best-price rule, which complicate value-based pricing efforts. Unlike other countries, the United States currently pays the highest prices globally for brand-name prescription drugs, which has prompted policymakers to consider IRP as a means to mitigate these costs.
Many countries that would potentially be included in a U.S. reference basket already employ IRP to varying degrees. Approximately two-thirds of comparator countries use IRP supplemented by other strategies like health technology assessments and domestic therapeutic reference pricing. Only a few rely solely on IRP as the primary mechanism for price negotiation, often being smaller countries with higher GDP per capita and lower drug spending than the United States. The most common method among these countries is to use the average price of drugs within the reference basket, though some use the lowest price as a benchmark.
Despite its appeal, IRP faces criticism and challenges. One major concern is that it cedes pricing decisions to foreign governments, whose valuations of medicines may differ significantly from U.S. perspectives. For instance, the British National Health Service typically assigns a value to health improvements that is substantially lower than American valuations. Furthermore, differences in price transparency complicate the benchmarking process; countries like Germany publish both list and net prices, influencing how other nations reference German prices during their negotiations. Additionally, price indexes often underestimate differences between U.S. and international prices, as they generally adjust U.S. prices downward without fully accounting for rebates and discounts common in other countries.
Development of the Proposal
Discussions regarding a revolutionary proposal to link U.S. drug prices to international standards emerged as part of the Trump administration’s broader efforts to reduce pharmaceutical costs. The concept, often referred to as the “most favored nation” model or international reference pricing (IRP), aimed to benchmark U.S. drug prices against prices paid by other high-income countries with similar economic profiles. Under this model, payments for certain high-cost, physician-administered drugs in the U.S. would be capped at no more than the lowest price drug manufacturers receive in comparable foreign markets, adjusted for purchasing power parity.
Initial indications suggested that the proposal was considered a mid-level priority within the administration’s agenda to tackle rising drug costs, with government health officials actively exploring the policy. However, the proposal had not been finalized, and specifics remained under deliberation by aides and policymakers. Reports indicated that President Trump had not personally approved the plan at the time, though he teased a “very big announcement” regarding drug pricing that insiders interpreted as related to this initiative.
The pharmaceutical industry responded with significant concern, viewing the proposed policy as an existential threat to the industry’s business model and to U.S. biosciences innovation. Industry groups such as PhRMA actively lobbied Congress against the policy, fearing that it could also prompt drugmakers to increase prices in reference countries to offset reduced revenues from the U.S. market. Despite this pushback, the proposal represented a notable shift from traditional U.S. drug pricing policies, which have historically allowed prices to remain higher than those in other countries.
At the time, it remained unclear whether the pharmaceutical industry’s alternative proposals would be accepted by the White House or if the administration would ultimately proceed with the most favored nation strategy. As aides continued to refine the plan, the policy’s potential impact on both domestic drug prices and international pharmaceutical markets was the subject of ongoing analysis and debate.
Proposal Details
The Trump administration’s proposal to link U.S. prescription drug prices to international standards centers around a “most favored nation” (MFN) pricing model. This approach aims to benchmark U.S. drug prices against those paid by a group of higher-income countries, effectively setting U.S. prices at or near the lowest price available among these peer nations, adjusted for per-capita gross domestic product (GDP). The model targets drugs covered under Medicare Part B, which includes physician-administered medications, with the goal of reducing Medicare spending on prescription drugs.
Under the MFN model, U.S. prices would be determined by referencing the lowest prices from an established basket of Organisation for Economic Co-operation and Development (OECD) countries with comparable economic statuses, specifically those with GDP per capita at least 60% that of the United States. This international reference pricing (IRP) mechanism is intended to foster price convergence, potentially aligning U.S. drug prices more closely with global averages. However, concerns exist about how this approach might affect pharmaceutical innovation and the valuation of new medicines, as foreign governments often assess drug value differently from the U.S..
Implementation would require significant regulatory changes, including relabeling eligible prescription drugs to meet U.S. standards and ensuring quality through testing for authenticity and degradation. The Food and Drug Administration (FDA) would oversee these processes, with the goal of maintaining public health and safety while promoting competition to lower costs. Moreover, price benchmarking under this system could influence not only the U.S. market but also global pharmaceutical pricing dynamics, as countries often reference each other’s prices in negotiations.
Previous efforts by the Department of Health and Human Services to reduce Medicare drug spending by tying prices to those of comparably wealthy countries faced legal challenges and were blocked in the courts. Nevertheless, the administration has continued to consider similar models, including pilot projects authorized under the Affordable Care Act to test alternative payment approaches. The MFN proposal thus represents a renewed and more comprehensive attempt to leverage international price comparisons to control domestic drug costs.
Expected Impact
The Trump Administration’s proposal to link U.S. drug prices to international standards was projected to save taxpayers more than $85 billion over seven years by cutting into the country’s annual drug spending, which exceeds $400 billion. The plan, often referred to as the “most-favored-nations rule,” aimed to set U.S. prices based on the lowest prices paid in Organisation for Economic Co-operation and Development (OECD) countries with comparable economic status, adjusted for per-capita GDP. This approach was intended to limit prices to rational estimates of their true value to patients without undermining incentives for medical innovation.
However, the proposal was met with concerns about its broader impact. Critics warned that the policy could be disruptive not only to the pharmaceutical market but also to the entire healthcare sector, potentially affecting innovation and leading to unintended health consequences for Americans. Research has indicated that shifting the U.S. pricing system to resemble the European model could result in shorter, less healthy lives, with economic losses amounting to trillions of dollars.
While the administration emphasized potential cost savings for taxpayers, it remained unclear whether the plan would exclusively target Medicare Part B drugs or include other medications covered under the program, as the proposal had not been finalized and was subject to change. Additionally, regulatory frameworks accompanying the proposal required eligible prescription drugs to undergo stringent testing and relabeling to ensure safety and authenticity before importation, aiming to protect public health while promoting competition to reduce drug prices.
Criticisms and Controversies
The proposal to link U.S. drug prices to the lower costs paid by other developed countries, often referred to as the “most-favored nation” or international reference pricing policy, faced significant criticism and controversy throughout its consideration under the Trump Administration. Industry groups, policymakers, and healthcare experts expressed concerns about the potential impact of such a policy on innovation, market dynamics, and the broader healthcare system.
Pharmaceutical companies viewed the policy as an existential threat to the industry and U.S. biosciences innovation, with some sources describing it as the top concern for the pharmaceutical sector compared to other government actions like tariffs on imported medicines. The industry feared that tying U.S. drug prices to international benchmarks could disrupt the entire healthcare market, not just pharmaceutical pricing, due to differences in drug availability and coverage across countries. For example, thousands of approved drugs in the U.S. are either not covered or not launched in some reference countries, complicating direct price comparisons and policy implementation.
Critics also argued that the administration may not have fully understood the broader consequences of the policy, particularly regarding innovation incentives in the pharmaceutical sector. The concern was that lower prices mandated by international referencing could reduce revenues that fund research and development, potentially slowing the development of new therapies. Additionally, legal and regulatory challenges, such as the Medicaid best-price rule and anti-kickback statutes, posed obstacles to adopting innovative, value-based pricing arrangements that could otherwise complement pricing reforms.
The policy also faced opposition rooted in political and lobbying efforts. The pharmaceutical industry, through groups like PhRMA, actively lobbied Congress to block the measure, leveraging long-standing resistance to government-imposed drug price controls. This resistance contributed to the rejection of earlier proposals and created a challenging environment for the Trump Administration’s efforts to lower drug prices via international reference pricing.
Moreover, technical and operational challenges complicated the feasibility of the proposal. Ensuring imported drugs meet U.S. labeling requirements, undergo authenticity testing, and comply with established standards is essential to protect public health and safety. The administration recognized the need to balance cost reductions with rigorous safeguards, but these added layers of complexity made swift implementation difficult.
Finally, judicial intervention halted a previous international reference pricing program during Trump’s first term, underscoring the legal hurdles such policies face. That program, initially projected to save taxpayers over $85 billion in seven years, was blocked by courts, reflecting the contentious and uncertain nature of these reforms.
Comparative Analysis
Price indexes serve as a crucial tool in isolating drug price differences by focusing solely on prices without the confounding effects of drug volume or mix variations. Calculations underpinning the analysis of the Trump administration’s proposal utilized 2018 data comparing U.S. prescription drug prices with those in 32 other countries. This method ensures that the comparison reflects price disparities rather than consumption patterns or drug types.
Despite their utility, these price indexes tend to understate the true magnitude of price differences. This occurs because adjustments are typically applied only to U.S. prices, lowering them to account for rebates and discounts, while similar or even more prevalent discounts in other countries remain unadjusted. Consequently, the reported price differentials between the United States and international markets are conservative estimates.
The proposed plan to link U.S. drug prices to international benchmarks relies on international reference pricing (IRP), wherein U.S. prices would be set in relation to prices paid by a basket of higher-income countries. Although concerns exist that such referencing might lead to global price convergence or upward price adjustments internationally, empirical analyses to date have not observed this effect. Still, policymakers remain wary of potential convergence, and industry stakeholders often favor differential pricing as a mechanism to maintain equity and prevent uniform price inflation.
Transparency of drug prices varies among countries and affects international referencing practices. For instance, Germany’s public availability of both list and net prices through the Rote Liste database facilitates referencing by other countries. Germany itself employs IRP selectively, using a basket of 15 European countries to establish ceilings or maximum reimbursements for innovative drugs lacking therapeutic competitors. This contrasts with countries like the UK and Canada, where net prices are less transparent. The German model of transparency and selective referencing informs negotiations and price-setting strategies relevant to the U.S. context.
Potential responses from drug manufacturers to international price referencing include renegotiating contracts with reference countries to increase their prices, thereby indirectly elevating the benchmark used for U.S. pricing. This dynamic underscores the complexity and potential unintended consequences of linking U.S. drug prices to international standards under the Trump plan.
Value-based pricing concepts have also influenced the discourse around pharmaceutical pricing reform during this period, emphasizing the alignment of drug prices with therapeutic value as part of broader policy considerations.
Outcome and Current Status
The “most-favored-nations” (MFN) rule, introduced as an interim final rule by the Trump Administration before leaving office in 2021, aimed to link U.S. drug prices to the lowest prices paid by certain Organisation for Economic Co-operation and Development (OECD) countries with comparable economic status, adjusted for per-capita GDP. The rule targeted lowering prescription drug costs by setting payment rates based on international reference prices, thereby aligning U.S. prices with those in countries with a GDP per capita of at least 60% that of the United States.
Despite its ambitious goals, the MFN rule faced considerable industry pushback, being described by pharmaceutical trade groups as a significant threat to U.S. biosciences innovation. The industry expressed concerns that such international reference pricing could lead to renegotiation of drug prices abroad, potentially driving prices up in other markets and complicating global pricing dynamics. Furthermore, government health officials treated the policy as a mid-level priority amidst a broader effort to reduce drug prices, alongside measures like tariffs on imported medicines.
The MFN rule was part of a set of four executive orders focusing on drug pricing, three of which addressed prescription drug importation, Medicare Part D drug rebates, and costs of insulin and injectable epinephrine in federally qualified health centers. However, the MFN proposal itself was not publicly released with the others, limiting transparency and complicating regulatory implementation. The rule also required further regulatory actions before becoming enforceable.
Subsequent legislative efforts, such as the Prescription Drug Price Relief Act of 2021, continued to explore similar mechanisms for drug price reduction based on international benchmarks. However, the rule’s legal enforceability was clarified as limited; an executive order accompanying the MFN model explicitly stated that it did not create any substantive or procedural rights enforceable against the federal government or its entities
The content is provided by Sierra Knightley, Lifelong Health Tips
